LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE – QNT Press Release


SALT LAKE CITY, June 6, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented “LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy” today at the 2022 Epilepsy Foundation Pipeline Conference. The conference is held every two years to bring together decision-makers in the field of epilepsy treatment, therapeutic innovation and development, showcasing the latest developments in the epilepsy pipeline. This forum provides an opportunity for evaluating new therapies in development, exploring future advancements, and encouraging collaborations and partnerships.

“We are excited to have been invited to present at this important event,” commented Dr. Patel. “Given the unique needs of Women With Epilepsy (WWE) and the limitations of currently available treatment options, we look forward to advancing our novel oral oral positive GABAA modulator for WWE of child bearing (CB) age.”

Pending US FDA clearance of its IND, Lipocine plans to conduct a proof-of-concept study in the second …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center